After adjusting for baseline variables , no relevant differences in major adverse cardiovascular and cerebrovascular events were observed at 1year ( prasugrel/clopidogrel : cardiac death 2.6 % / 4.2 % , myocardial infarction 2.7 % / 3.8 % , revascularisation 5.9 % / 6.7 % , stroke 1.0 % / 1.6 % ) .